Howell SJ, Coe F, Wang X, Horsley L, et al. Carboplatin dose capping affects pCR rate in HER2-positive breast cancer patients treated with neoadjuvant Docetaxel, Carboplatin, Trastuzumab, Pertuzumab (TCHP). Breast Cancer Res Treat 2020 Aug 29. pii: 10.1007/s10549-020-05868.
PMID: 32860550